Expert Commentary
India’s ₹50 Crore Drug-Discovery Track: Balancing Investor Access and Scientific Merit
Sudha Chandrashekar, Swasti; Umesh Chawla, Swasti
22 Oct 2026
Opinion • Grassroots Voices • Policymakers Perspectives • Expert Analysis • Policy Briefs
Sudha Chandrashekar, Swasti; Umesh Chawla, Swasti
Anmol Aggarwal, Venus Remedies Limited
Rishikesh Narayan, IIT Goa